Antiviral Indoles

A compound of formula (I):

• wherein
• Ar is a moiety containing at least one aromatic ring and possesses 5-, 6-, 9- or 10-ring atoms optionally containing 1, 2 or 3 heteroatoms independently selected from N, O and S, which ring is optionally substituted by groups Q1 and Q2;
• Q1 is halogen, hydroxy, C1-6alkyl, C1-6alkoxy, aryl, heteroaryl, CONRaRb, (CH2)0-3NRaRb, O(CH2)1-3NRaRb, O(CH2)0-3CONRaRb, O(CH2)0-3aryl, O(CH2)0-3heteroaryl, 0(CReRf)aryl, O(CReRf)heteroaryl or OCHRcRd;
• Ra and Rb are each independently selected from hydrogen, C1-4alkyl and C(O)C1-4alkyl;
• or Ra, Rb and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, where said ring is optionally substituted by halogen, hydroxy, C1-4alkyl or C1-4alkoxy;
• Rc and Rd are each independently selected from hydrogen and C1-4alkoxy;
• or Rc and Rd are linked by a heteroatom selected from N, O and S to form a heteroaliphatic ring of 4 to 7 ring atoms, where said ring is optionally substituted by halogen, hydroxy, C1-4alkyl or C1-4alkoxy;
• and wherein said C1-4alkyl, C1-4alkoxy and aryl groups are optionally substituted by halogen or hydroxy;
• Re is hydrogen or C1-6alkyl;
• Rf is C1-6alkyl;
• Q2 is halogen, hydroxy, C1-4alkyl or C1-4alkoxy, where said C1-4alkyl and C1-4alkoxy groups are optionally substituted by halogen or hydroxy;
• or Q1 and Q2 may be linked by a bond or a heteroatom selected from N, O and S to form a ring of 4 to 7 atoms, where said ring is optionally substituted by halogen, hydroxy, C1-4alkyl or C1-4alkoxy;
• A is C3-6alkyl or C2-6alkenyl,
• or A is a non-aromatic ring of 3 to 8 ring atoms where said ring may contain a double bond and/or may contain a O, S, SO, SO2 or NH moiety,
• or A is a non-aromatic bicyclic moiety of 4 to 8 ring atoms,
• and A is optionally substituted by halogen, hydroxy, C1-4alkyl or C1-4alkoxy;
• D is N or CRg;
• Rg is hydrogen, fluorine, chlorine, C1-4alkyl, C2-4alkenyl or C1-4alkoxy, where said C1-4alkyl, C2-4alkenyl and C1-4alkoxy groups are optionally substituted by hydroxy or fluorine;
• W is a bond, C═O, O, S(O)0-2 or —(CR10R11)—(CR12R13)0-1—;
• X is —CR14a— or N;
• Y is a bond, C═O, O, —CR14R15— or NR14;
• and Z is a bond, C50 O, O, S(O)0-2 or —(CR10R11)—(CR12R13)0-1— or NR10;
• and none, one or two of W, Y and Z are a bond;
• or X is C═O, O, —CR14bR15b— or NR14b;
• and Y is hydrogen or absent and Z is hydrogen or a group Q1 or Q2
• R10, R11, R12, R13, R14, R14a, R14b, R15 and R15b are each independently selected from hydrogen, hydroxy, C1-6alkyl, C2-6alkenyl, C1-6alkoxy, C(O)C1-6alkyl, Het, (CH2)0-3NR16R17, C(O)(CH2)0-3NR16R17, NHC(O)(CH2)0-3NR16R17, O(CH2)1-3NR16R17, S(O)0-2(CH2)0-3NR16R17 and C(O)(CH2)0-3OR16;
• or one of R10, R14, R14a and R14b is linked to R22 or R23 to form a ring of 4 to 10 atoms, where said ring is optionally substituted by halogen, hydroxy, C1-4alkyl or C1-4alkoxy;
• or, when X is —CR14a— and Z is —CR10R11— or NR10, R10 is joined to R14a to form a —(CH2)—1-4 group, optionally substituted by C1-4alkyl;
• Het is a heteroaliphatic ring of 4 to 7 ring atoms, which ring may contain 1, 2 or 3 heteroatoms selected from N, O or S or a group 5(O), S(O)2, NH or NC1-4alkyl;
• R16 and R17 are independently selected from hydrogen, C1-6alkyl and (CH2)0-4NR18R19;
• or R16, R17 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, which ring may optionally contain 1 or 2 more heteroatoms selected from O or S or a group S(O), S(O)2, NH or NC1-4alkyl, and which ring is optionally substituted by halogen, hydroxy, C1-4alkyl or C1-4alkoxy;
• R18 and R19 are independently selected from hydrogen and C1-6alkyl;
• or R18, R19 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, which ring may optionally contain 1 or 2 more heteroatoms selected from O or S or a group S(O), S(O)2, NH or NC1-4alkyl, and which ring is optionally substituted by halogen, hydroxy, C1-4alkyl or C1-4alkoxy;
• R1 is hydrogen or C1-6alkyl;
• B is —CR20R21—, —C(═O)—, —SO— or —SO2—;
• R20 and R21 are independently selected from hydrogen and C1-6alkyl;
• or R20 and R21, together with the carbon atom to which they are joined, form a C3-6cycloalkyl group;
• M is C4-8alkylene or C4-8alkenylene, optionally substituted by R22, where 1, 2 or 3 of the carbon atoms in the C4-8alkylene or C4-8alkenylene groups is optionally replaced by O, NR23, S, SO, SO2, piperidinyl, piperazinyl or pyrrolidinyl,
• where each R23 is independently hydrogen, C1-6alkyl, C2-6alkenyl, (CH2)0-3C3-6cycloalkyl, (CH2)1-3OH, C1-6alkoxy, C(O)C1-6alkyl, (CH2)0-3aryl, (CH2)0-3Het, (CH2)0-3heteroaryl, (CH2)1-3NR16R17, C(O)(CH2)1-3NR16R17, S(O)0-2(CH2)1-3NR16R17, C(O)(CH2)1-3OR16, (CH2)1-3(CH2)0-3aryl,
• or R23 is linked to one of R10, R14, R14a and R14b to form a ring of 4 to 10 atoms as hereinbefore described;
• or where 2 or 3 of the carbon atoms in the C4-8alkylene or C4-8alkenylene group are replaced by NR23, then the R23 groups can be joined to form a —(CH2)—1-3 group, optionally substituted by C1-2alkyl,
• where R22 is halo, C1-4alkyl, (CH2)0-3C3-8cycloalkyl, (CH2)0-3aryl, (CH2)0-3heteroaryl, (CH2)0-3Het, oxo or (CH2)0-3NR16R17,
• or R22 is linked to one of R10, R14, E14a and R14b to form a ring of 4 to 10 atoms as hereinbefore described;
• and pharmaceutically acceptable salts thereof.